Abstract
IntroductionRandomised controlled trials have demonstrated efficacy of vedolizumab in Ulcerative Colitis (UC) and Crohn’s Disease (CD). Further data in the real-world setting is needed to inform future practice.MethodsA multicentre retrospective...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
